Recurrent Osteosarcoma Completed Phase 2 Trials for Sorafenib (DB00398)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00330421Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)Treatment